Startup Deep Dive : Onco.com — the virtual cancer hospital that had the patients but never the unit economics

Onco.com did something Indian healthcare rarely manages: it built what its lead investor Accel called India’s first virtual cancer hospital, signed up more than 30,000 patients across 18 countries by its own count, and pulled $7 million (about ₹67 crore) out of Accel and Chiratae Ventures to do it. Demand was never the problem. By the peak, the platform was drawing 25,000-plus visitors and over 1,000 organic cancer-patient leads a month, all without paid marketing, according to the account its own chief executive later gave.

And yet, in the summer of 2025, the independent company stopped running. Its CEO, OkCredit co-founder Harsh Pokharna, wrote publicly that the digital-only model’s numbers did not close: the margins were eaten by collections and compliance, the revenue per patient too thin. The brand did not simply vanish, though. Apollo Hospitals had quietly bought Onco in December 2024, a deal that surfaced only in July 2025. This is the story of a company that solved the hardest part of cancer care, patient trust and access, and still could not make the arithmetic work on its own.

Quick facts

What Onco.com actually did

Onco.com sold guidance and access, not drugs or scans. It positioned itself as an internet aggregator in cancer care, sitting between a newly diagnosed patient and the fragmented Indian oncology system, and managing the journey end to end. At its 2019 Series A the company said it connected patients to a network of over 1,500 oncologists from India and the United States and more than 500 treatment centres, and claimed to handle around 10,000 unique cancer cases month on month (company-stated, via Inc42, September 2019). The core promise was a second opinion and a coordinated plan for a disease where a wrong first move is expensive and sometimes fatal.

The customer was the patient and the family, not the hospital. Over time the platform layered on online consultations, booking of treatment packages, peer-to-peer support, and medicine delivery, describing the whole as India’s first virtual cancer hospital when Accel led its round.

The founding insight

The insight came from both sides of the cancer problem: the clinical and the operational. Rashie Jain is an IIT Kanpur engineer, with a degree in biological sciences and bioengineering, and a healthcare-management MBA from the Wharton School. She had spent more than a decade in the sector, including a business-development stint at the biotech company Amgen, before she started Onco. Her co-founder, Dr Amit Jotwani, is a practising oncologist who had watched, up close, how Indian patients actually move through a diagnosis.

What they saw was not a shortage of doctors but a shortage of navigation. A cancer diagnosis in India typically lands a family into a maze of specialists, second opinions, labs, and treatment centres with no one coordinating the sequence, and the cost of a wrong or delayed decision is measured in both money and survival. Onco was built to be that coordinator, using a global panel of oncologists to give patients a reviewed plan rather than a single doctor’s verdict. The founders registered the operating entity, Netdox Health Private Limited, in Bengaluru in July 2017, with Jain and Jotwani as directors.

The struggle years

Onco’s difficulty was structural, and it showed up early. Selling to cancer patients is selling to people at their most frightened and their most cash-strapped, and the willingness to pay for advice, as opposed to treatment, is low. The company kept widening what it did, from second opinions into consultations, package bookings, peer support and medicine delivery, in search of a service the patient would actually pay for repeatedly.

The financials tell the strain plainly. Even in its later years the operating company stayed small and loss-making: Netdox Health booked revenue of only ₹4.17 crore in the year to March 2024, and that top line actually shrank about 28.2% from the year before, per data filed with the Ministry of Corporate Affairs and aggregated by Tofler and Tracxn. A company that had raised millions and served tens of thousands of patients was, on the books, a few-crore business going backwards. The second, quieter near-death was leadership itself: by the final phase the company was being run not by its clinical-founder duo but by Harsh Pokharna, the OkCredit co-founder who had first come in as an investor around 2020, a sign that the original operating plan had already been handed over.

The turning point

The turning point was a sale dressed, at first, as a shutdown. In early July 2025, Pokharna posted on LinkedIn that Onco had stopped operating, and he was blunt about why. At its peak, he wrote, the platform had 25,000-plus monthly visitors and over 1,000 unique cancer-patient leads a month, entirely organic, across its website, app and social channels, and it still did not work as a standalone business. His diagnosis of the model was that margins get eaten alive by collections and compliance costs, and that the unit economics do not close for digital-only solutions because of low average revenue per user.

What the shutdown talk missed was that Apollo Hospitals had already bought the company in December 2024. The deal, with terms undisclosed, only became public in July 2025, reported by Inc42 and Outlook Business, and confirmed on registry aggregators, which list Onco’s status as acquired by Apollo Hospitals on 8 July 2025. So the two numbers that sit on either side of the turning point are stark: 1,000-plus organic patient leads a month on one side, and a standalone business too thin to fund on the other, resolved by a strategic buyer folding the brand into a hospital chain that already owns the treatment, and therefore the margin.

The money behind it

Onco’s funding was venture-backed but modest by healthtech standards, and the totals reported vary by source:

• Series A, $7 million (about ₹67 crore): announced 26 September 2019, led by Accel with Chiratae Ventures and Japan’s Dream Incubator (Inc42, September 2019). This is the round Onco is best known for.
• Debt financing, around December 2020: Inc42’s company record lists a debt round, with Alteria Capital named among backers across Onco’s history (Inc42; Tracxn).
• Total raised, reported range: Inc42’s company page puts lifetime funding at roughly $8.22 million, while Tracxn, Outlook Business and Inc42’s acquisition report cite about $13 million across five rounds. The lower figure reflects disclosed equity; the higher includes later and debt rounds. Treat the total as reported, not audited.
• Named backers: Accel and Chiratae Ventures (lead institutional investors), Dream Incubator, Rainmatter (Zerodha’s fund), Alteria Capital (venture debt), and AMEA Ventures appear across the rounds (Inc42; Tracxn; Outlook Business).
• Angel-turned-operator: Harsh Pokharna, co-founder of OkCredit, invested around 2020 and later ran the company as CEO in its final phase (Digital Health News; Inc42).

What each mattered for: Accel’s cheque and its “virtual cancer hospital” framing gave Onco national credibility and hiring firepower in 2019; Rainmatter and the venture-debt line kept a low-revenue business alive through the difficult stretch after; and Pokharna’s move from cheque-writer to CEO marked the point where the company was being managed for an outcome rather than for growth.

How it made money

Onco’s economics are the whole story, so it is worth being precise about where the rupees came in and where they leaked out:

• Money in: paid online oncology consultations and second opinions; commissions or margins on treatment packages booked through partner hospitals and centres; and medicine delivery through its aggregator platform.
• The take-rate problem: as an aggregator, Onco captured only a slice of each treatment’s value while the hospital kept the bulk, so its revenue per patient stayed low even when the patient spent heavily on the actual cancer treatment.
• Costs out: Pokharna singled out collections and compliance as the margin killers, the operational cost of chasing payments and meeting healthcare rules on a per-transaction basis (LinkedIn, via Digital Health News, 2025).
• The part people get wrong: the bottleneck was never traffic or trust. Onco had both, tens of thousands of patients and 1,000-plus free leads a month. What it lacked was a repeatable, high-margin line item; cancer is often a once-in-a-lifetime spend per family, so lifetime value is capped and re-purchase is rare.

The numbers

Onco’s operating entity, Netdox Health Private Limited, was always small on the books. The figures below are from filings with the Ministry of Corporate Affairs as aggregated by Tofler and Tracxn; where an absolute figure was behind a paywall it is left out rather than estimated.

• FY24 revenue: ₹4.17 crore, a contraction of roughly 28.2% from FY23 (Tofler/Tracxn, from MCA).
• FY24 loss: ₹3.34 crore, meaning the business lost close to eight rupees for every ten it earned that year (Tracxn, from MCA).
• Longer trend: Tofler reports a five-year revenue CAGR of about 41%, but with FY24 turning down, growth had clearly stalled ahead of the sale.
• Capital base: paid-up capital of ₹12.94 lakh against authorised capital of ₹30 lakh (Tofler/Zauba, from MCA), a reminder that most of the money came as premium-priced venture equity, not share capital.

Where the money came from

Onco’s revenue mix and reach are less documented than its funding, but the disclosed splits point in one direction:

• Patient base was global, revenue was not: the company said it served over 30,000 patients across 18 countries (company-stated at Series A, Inc42, September 2019), yet its filed revenue stayed in the low single-digit crores, so international reach did not translate into international-scale income.
• Supply network: 1,500-plus oncologists from India and the US and 500-plus treatment centres formed the supply side (company-stated, Inc42, 2019); the value the platform created largely accrued to those partners, not to Onco.
• Organic, not paid, demand: the 25,000-plus monthly visitors and 1,000-plus monthly leads were organic (Pokharna, 2025), meaning customer-acquisition cost was low, an unusually healthy funnel that still could not save the model.
• The surprise: the classic startup killer is expensive customers. Onco’s problem was the opposite. It had cheap, high-intent demand and still lost money, because the value per case was captured downstream by hospitals and pharmacies, not by the navigator.

The risks that caught up

• Low ARPU in a once-in-a-lifetime purchase: cancer care is typically a single, intense episode per family, so there is little repeat business and lifetime value is capped. Pokharna named low average revenue per user as a core reason the digital-only model failed (Digital Health News, 2025). This is the risk that actually killed the standalone company.
• Thin aggregator margins against heavy operating costs: collections and compliance costs scale with every transaction and every regulation, while an aggregator’s cut of each treatment is small. When those two lines cross, more volume does not fix the loss, which is why 1,000 leads a month was not enough.
• Dependence on partners who own the margin: hospitals, labs and pharmacies captured the bulk of each patient’s spend. A navigator that does not own treatment capacity is structurally squeezed, which is precisely why the resolution was acquisition by a hospital chain (Apollo) rather than another funding round.

The takeaway

Onco.com is a clean lesson in the difference between demand and a business. The company proved, at real scale, that Indian cancer patients would come to a trusted digital front door: tens of thousands of them, from 18 countries, mostly for free. That is the hard part, and Onco genuinely solved it. What it could not solve was owning enough of the money that moved once the patient walked through that door. In a disease where the treatment, not the advice, carries the value, a pure navigator sits in the wrong seat.

The transferable point is this: intent-rich, low-cost demand is necessary but not sufficient. If the margin lives one step downstream, with the hospital or the pharmacy, then the platform that generated the demand will eventually have to either move into treatment itself or be bought by someone who already has it. Apollo, which owns the beds and the oncology, could make Onco’s traffic pay in a way Onco never could alone. That is not a failure of product or of trust. It is a reminder that in healthcare, whoever owns the treatment owns the economics.

Frequently asked questions

Who founded Onco.com and when?

Onco.com was founded in 2016 by Rashie Jain, an IIT Kanpur engineer with a Wharton healthcare MBA and a background at Amgen, and Dr Amit Jotwani, a practising oncologist. The operating company, Netdox Health Private Limited, was incorporated in Bengaluru in July 2017.

How much funding did Onco.com raise?

Its best-known round was a $7 million (about ₹67 crore) Series A in September 2019, led by Accel with Chiratae Ventures and Dream Incubator. Lifetime funding is reported in a range: roughly $8.22 million by Inc42’s company page, and about $13 million across five rounds by Tracxn, Outlook Business and Inc42’s acquisition report, including venture debt from Alteria Capital and investment from Rainmatter.

Did Onco.com shut down or get acquired?

Both framings are true. Apollo Hospitals acquired Onco in December 2024 (reported July 2025, terms undisclosed), so the brand did not disappear. But the standalone digital business stopped operating, and its CEO Harsh Pokharna said publicly that the digital-only unit economics did not work.

Why did Onco.com’s business model struggle?

As an aggregator it earned thin margins on consultations, treatment-package bookings and medicine delivery, while hospitals and pharmacies captured most of each patient’s spend. With low average revenue per user in a once-in-a-lifetime purchase, and collections and compliance costs eating margins, the model lost money despite strong organic demand.

What are the founders doing now?

After the Apollo deal, Rashie Jain moved on to build Marvix AI, a generative-AI platform for automating clinicians’ administrative work, while Dr Amit Jotwani returned to clinical practice, reported to be at Medicover Hospitals in Hyderabad (Inc42; Outlook Business, 2025).

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• Inc42 — “Cancer Care Startup Onco Raises $7 Mn From Accel, Chiratae, Others” (September 2019)
• Inc42 — “Apollo Hospitals Acquires Accel-Backed Healthtech Startup Onco” (July 2025)
• Inc42 — Onco company profile / latest funding and financials (September 2026)
• Outlook Business — “Apollo Hospitals Acquires Cancer-Care Platform Onco.com” (July 2025)
• Digital Health News — “Cancer Care Startup Onco Shuts Down Amid Unit Economics Challenge” (2025)
• Tracxn — Onco company profile and Netdox Health Private Limited legal-entity page (September 2026)
• Tofler — Netdox Health Private Limited financials, CIN U85320KA2017PTC104409 (from MCA filings)
• Zauba Corp — Netdox Health Private Limited registration and director details (from MCA)
• Accel / SeedToScale — “Investment in Virtual Cancer Care: Onco.com launches India’s first Virtual Cancer Hospital” and “Reimagining Cancer Care in India — the Onco.com Story”
• YourStory — Rashie Jain profile and Onco.com UpClose feature
• Trading Economics — USD/INR reference rate, 18 September 2026

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.